Vertex picks cystic fibrosis triple combos for Phase III trials

(Reuters) - Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

from Reuters: Health News http://ift.tt/2BHFtaf
via IFTTT